

## Appendix 3E

### Daily share buy-back notice (except minimum holding buy-back and selective buy-back)

Information and documents given to ASX become ASX's property and may be made public.

Name of entity	ABN/ARSN
Sigma Pharmaceuticals Limited	15 088 417 403

We (the entity) give ASX the following information.

#### Information about buy-back

1	Type of buy-back	On-market buy-back
2	Date Appendix 3C was given to ASX	13 September 2012 (Associated Appendix 3D dated 2 October 2014)

#### Total of all shares/units bought back, or in relation to which acceptances have been received, before, and on, previous day

	Before previous day	Previous day
3	Number of shares/units bought back or if buy-back is an equal access scheme, in relation to which acceptances have been received	100,241,914 449,757
4	Total consideration paid or payable for the shares/units	\$72,373,804 \$366,372

**Appendix 3E**  
**Daily share buy-back notice**

Before previous day	Previous day
---------------------	--------------

5 If buy-back is an on-market buy-back	Highest price paid: \$0.8525	Highest price paid: \$0.8350
	Lowest price paid: \$0.5600	Lowest price paid: \$0.8100 Highest price allowed under rule 7.33: \$0.8927

**How many shares/units may still be bought back?**

6 If the company/trust has disclosed an intention to buy back a maximum number of shares/units – the remaining number of shares/units to be bought back	17,938,681
---------------------------------------------------------------------------------------------------------------------------------------------------------	------------

**Compliance statement**

1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.
2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

*or, for trusts only:*

1. The trust is in compliance with all requirements of the Corporations Act as modified by Class Order 07/422, and of the trust's constitution, relevant to this buy-back.
2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.



Sign here:  
(Director/Company secretary)

Date: 5 June 2015

Print name: SUE MORGAN

=====

For personal use only